Nasdaq · CIK 0000879407 · PHARMACEUTICAL PREPARATIONS
ARROWHEAD PHARMACEUTICALS, INC.
ARWR chart by TradingView
PRICE HISTORY
LIVE · NASDAQARWR chart by TradingView
- REVENUE FY2025 ENDED SEP 2025
- $0.8B
- EBITDA
- $0.1B
- FREE CASH FLOW
- $0.2B
- EPS
- $-0.01
- GROSS MARGIN
- —
- ROIC
- —
Q3 FY26ENDED JUN 2026HOVERDRAG ACROSS ANY CHART TO SCRUB ALL 24 · 40 QUARTERS SHOWNVALUATIONGROWTHPROFITABILITY & RETURNSCASH & CAPITALBALANCE SHEET
VALUATION
what you pay for a unit of the business7 CHARTS⤢
P / E RATIO (TTM)
—
-75%41.0x306.8x
⤢
P / SALES (TTM)
17.5x
+71%3.1x938.9x
⤢
P / BOOK
25.1x
+539%2.5x44.6x
⤢
EV / EBITDA (TTM)
—
⤢
EV / REVENUE (TTM)
—
⤢
FCF YIELD (TTM)
-0.64%
+9.3pp-25.12%11.26%
⤢
DIVIDEND YIELD (TTM)
—
GROWTH
is the business getting bigger5 CHARTS⤢
REVENUE
$0.1B
+240710%⤢
EBITDA (DERIVED)
$-0.2B
$0.1B⤢
NET INCOME
$-0.2B
$0.2B⤢
EPS (DILUTED)
$-1.36
$1.21⤢
REVENUE GROWTH YOY
171.02%
+199.6pp-100.00%27784.11%
PROFITABILITY & RETURNS
what survives to the bottom, and what it earns on capital4 CHARTS⤢
FCF MARGIN
-240.95%
+41019.4pp-41260.38%782.38%
⤢
RETURN ON CAPITAL
—
⤢
RETURN ON EQUITY (TTM)
-68.73%
+16.8pp-1216.44%35.58%
MARGIN FUNNEL
every line is a share of the same revenue, so they read on one scale — the gaps are what each layer takes out, and net rises above operating when income arrives from outside the businessGROSS MARGIN—
OPERATING MARGIN-226.03%
NET MARGIN-258.17%
FCF MARGIN-240.95%
CASH & CAPITAL
where the money actually goes5 CHARTS⤢
FREE CASH FLOW
$-0.2B
$0.2B⤢
STOCK-BASED COMP
$0.0B
+267%⤢
CAPITAL EXPENDITURE
$0.0B
+42%⤢
SHARES OUTSTANDING
0.14B
+94%⤢
DIVIDEND / SHARE
—
BALANCE SHEET
how much cushion there is3 CHARTS⤢
CASH & EQUIVALENTS
—
-19%⤢
TOTAL DEBT
—
⤢
DEBT / EBITDA (TTM)
—
OWNERSHIP
10 LARGEST HOLDERS · WHO OWNS THE FLOATINSTITUTIONS 84.04%INSIDERS 3.67%OTHER / RETAIL 12.30%628 INSTITUTIONAL FILERS
| HOLDER | % HELD | SHARES | VALUE | CHANGE |
|---|---|---|---|---|
| Blackrock Inc. | 12.89% | 18.2M | $1.59B | -14.8% |
| Avoro Capital Advisors LLC | 7.60% | 10.7M | $937.9M | +0.7% |
| FMR, LLC | 5.16% | 7.3M | $636.9M | +11.4% |
| Vanguard Portfolio Management LLC | 5.07% | 7.1M | $626.4M | NEW |
| State Street Corporation | 4.61% | 6.5M | $569.4M | +1.4% |
| Vanguard Capital Management LLC | 4.28% | 6.0M | $528.7M | NEW |
| Geode Capital Management, LLC | 3.04% | 4.3M | $375.0M | +31.1% |
| Fred Alger Management, LLC | 2.37% | 3.3M | $293.0M | +82.3% |
| Invesco Ltd. | 2.33% | 3.3M | $287.5M | +498.9% |
| Vestal Point Capital, LP | 1.62% | 2.3M | $199.4M | +152.8% |
AS OF 2026-03-31 · MOST RECENT 13F FILINGS
SOURCE → 10-K · 10-Q · 8-K / GUIDANCE · ALL FILINGS
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.